
Nykron 300/0.5mg Tablet
Salt Composition: Netupitant, Palonosetron
Expiry Date: 01/2028
Inclusive of all taxes
1 Tablet in Strip
About The Product
Nausea and Vomiting due to chemotherapy
Description
Nykron 300/0.5mg tablet is the prescription based antiemetic combination medication that used in the treatment of vomiting, nausea and other side effects which is caused due to chemotherapy. The medicine contains two active ingredient is Netupitant and Palonosetron.
They belong to the drug class of NK1 receptor antagonists and 5-HT3 receptor antagonists, respectively, and work together to prevent chemotherapy-induced nausea and vomiting. Doctor's prescription is necessary while taking the medication for correct dose and duration of the tablet.
Uses
Reduced nausea and vomiting due to chemotherapy
Side Effects
- Headache
- Fatigue or weakness
- Constipation
- Skin redness
- Indigestion
- Difficulty breathing
- Swollen face/ tongue
- Rash
- Muscle stiffness
- Rapid heart rate
How To Use
- Nykron 300/0.5mg tablet should be taken one hour before start of chemotherapy.
- The medicine is taken with or without food at the same time everyday to improve the absorption level in the body.
- Hence, the correct dose and duration of the medicine is only administered by the healthcare provider to enhance the effectiveness of the treatment.
How It Works
Nykron 300/0.5mg tablet is antiemetic combination medication that contain two active ingredient Netupitant that blocks neurokinin‑1 (NK1) receptors, which helps to prevent delayed nausea and vomiting. While Palonosetron blocks 5‑HT3 (serotonin) receptors that reduce acute nausea and vomiting during and soon after chemotherapy.
They both work together and provide long lasting protection from such types of side effects.
Safety Advice
FAQs
Nykron 300/0.5mg tablet reduce symptoms such as nausea, vomiting and other symptoms after chemotherapy.
It gives patients relief from side effects and helps improve their comfort during cancer treatment.
References
- Lorusso, V., Russo, A., Giotta, F., & Codega, P. (2020). Management of chemotherapy-induced nausea and vomiting (CINV): a short review on the role of netupitant-palonosetron (NEPA). Core evidence, 21-29.
- Shirley, M. (2021). Netupitant/palonosetron: a review in chemotherapy-induced nausea and vomiting. Drugs, 81(11), 1331-1342.
- Keating, G. M. (2015). Netupitant/palonosetron: a review in the prevention of chemotherapy-induced nausea and vomiting. Drugs, 75(18), 2131-2141.
- Aapro, M., Jordan, K., Scotté, F., Celio, L., Karthaus, M., & Roeland, E. (2022). Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice. Current Cancer Drug Targets, 22(10), 806-824.
- Lorusso, V. (2016). Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron. Therapeutics and Clinical Risk Management, 917-925.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
